|
CN104761637B
(zh)
|
2006-03-31 |
2021-10-15 |
中外制药株式会社 |
调控抗体血液动力学的方法
|
|
CN101874042B9
(zh)
|
2007-09-26 |
2019-01-01 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
|
EP2275443B1
(en)
|
2008-04-11 |
2015-12-02 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
|
TWI654204B
(zh)
|
2010-11-30 |
2019-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
具有鈣依存性的抗原結合能力之抗體
|
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
|
SG10201710322VA
(en)
|
2014-12-19 |
2018-02-27 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
|
NZ730607A
(en)
|
2014-12-19 |
2022-07-01 |
Chugai Pharmaceutical Co Ltd |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
|
WO2016125495A1
(en)
|
2015-02-05 |
2016-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
|
|
AU2017269839A1
(en)
|
2016-05-27 |
2018-11-22 |
Alexion Pharmaceuticals, Inc. |
Methods for treatment of refractory generalized myasthenia gravis
|
|
WO2017218515A1
(en)
|
2016-06-14 |
2017-12-21 |
Regeneron Pharmaceuticals, Inc. |
Anti-c5 antibodies and uses thereof
|
|
BR112019001902A2
(pt)
|
2016-08-05 |
2019-07-09 |
Chugai Seiyaku Kabushiki Kaisha |
composição para profilaxia ou tratamento de doenças relacionadas à il-8
|
|
BR112019018429A2
(pt)
*
|
2017-03-06 |
2020-04-14 |
Univ Pennsylvania |
anticorpo, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indíviduo e para reduzir a atividade de um sistema complemento de um indivíduo, e, célula
|
|
BR112020001703B1
(pt)
|
2017-07-27 |
2024-01-02 |
Alexion Pharmaceuticals, Inc |
Solução aquosa estável compreendendo um anticorpo anti-c5, método para produção desta solução, uso da mesma para tratar uma condição associada ao complemento e kit terapêutico compreendendo a mesma
|
|
EP3700928A1
(en)
|
2017-10-26 |
2020-09-02 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)
|
|
MX2020006113A
(es)
|
2017-12-13 |
2020-08-24 |
Regeneron Pharma |
Combinaciones de anticuerpos anti-c5 y usos de las mismas.
|
|
US12404320B2
(en)
|
2018-05-31 |
2025-09-02 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
|
|
JP7577542B2
(ja)
|
2018-06-04 |
2024-11-05 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
|
|
EP3814373A1
(en)
|
2018-06-28 |
2021-05-05 |
Alexion Pharmaceuticals, Inc. |
Methods of producing anti-c5 antibodies
|
|
US12098190B2
(en)
|
2018-09-06 |
2024-09-24 |
The Trustees Of The University Of Pennsylvania And |
Humanized anti-C5 antibodies and uses thereof
|
|
MX2021004994A
(es)
|
2018-10-30 |
2021-06-15 |
Alexion Pharma Inc |
Dosificacion subcutanea y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh).
|
|
CN116194478A
(zh)
|
2020-06-24 |
2023-05-30 |
阿雷克森制药公司 |
皮下（sc）施用抗c5抗体治疗补体相关病症
|